Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a clinical-stage biotech company with an innovative pipeline, including GRI-0621, a potential treatment for psoriasis and acne, and GRI-0803, a potential treatment for autoimmune disorders like lupus and multiple sclerosis. With a large market potential for lupus and a strong balance sheet and raised funds, GRI Bio's current valuation is attractive, offering significant upside potential. However, risks such as balance sheet/liquidity, product efficacy and regulatory approvals, and market competition should also be considered.

Bears say

GRI Bio is a clinical stage biotech company with two potential drug candidates, GRI-0621 for IPF and GRI-0803 for autoimmune disorders, in its pipeline. However, there are significant market risks due to competition, changing macroeconomic factors, and potential failure of product candidates to demonstrate safety and efficacy in clinical trials. Additionally, the company has no current revenue and a high net loss, which could create balance sheet and liquidity risks in the future. These factors contribute to the negative outlook on GRI Bio's stock.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.